Jiedu Huayu Oral Prescription

Phase 3Small molecule

Jiedu Huayu Oral Prescription is one of 8 small molecule programs targeting Cerebral Amyloid Angiopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral Amyloid AngiopathyActive, not recruiting

Cerebral Amyloid AngiopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Cerebral Amyloid Angiopathy

#DrugCompanyPhaseTrials

Minocin

TTriax

Approved

—2

Colcrys

Alnylam Pharmaceuticals

Phase 2

1 3

Jiedu Huayu Oral Prescription

BBeijing Tiantan Hospital

Phase 3

1 4

Amyloid PET

NNational Taiwan University Hospital

Phase 3

1 5

RG6026

Bayer Aspirin

Plavix

ALN-APP

Alnylam Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Cerebral Amyloid Angiopathy

NCT07250035

Clinical

Trials by Indication[1]

Cerebral Amyloid Angiopathy1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study of Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy

Recruiting·BBeijing Tiantan Hospital·Phase 3·NCT07250035·436 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Jiedu Huayu Oral Prescription. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Jiedu Huayu Oral Prescription compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Jiedu Huayu Oral Prescription. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Tiantan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Tiantan Hospital

Jiedu Huayu Oral Prescription

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Cerebral Amyloid Angiopathy1 trial

References

Drug Info

Quick Facts

Related News